Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Feb;10(2):104125.
doi: 10.1016/j.esmoop.2024.104125. Epub 2025 Jan 21.

Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world

E Blondeaux  1 , L Boni  2 , G Chilà  3 , A Dri  4 , R Caputo  5 , F Poggio  6 , A Fabi  7 , G Arpino  8 , F Pravisano  4 , E Geuna  3 , V Delucchi  2 , T Ruelle  9 , I Giannubilo  9 , M De Laurentiis  5 , F Puglisi  10 , C Bighin  6 , M Lambertini  11 , F Montemurro  12 , L Del Mastro  11
Affiliations
Observational Study

Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world

E Blondeaux et al. ESMO Open. 2025 Feb.

Abstract

Background: Estimating patient attrition across lines of treatment (i.e. the probability that upon treatment failure the patient will not be able to receive a subsequent treatment) may be a valuable tool for optimizing treatment sequencing. We sought to describe the first-to-second-line attrition rate and factors associated with attrition in a real-world cohort of patients with metastatic breast cancer.

Methods: The Gruppo Italiano Mammella (GIM)14/BIO-META (NCT02284581) is an ongoing, ambispective observational multicenter study enrolling patients with metastatic breast cancer receiving first-line therapy. In patients experiencing disease progression, attrition was defined as no further anticancer treatment and death within 6 months from the end of first-line therapy. The attrition rate from the first-to-second line was studied by descriptive analyses and univariate and multivariable logistic models were used to explore potentially predictive factors.

Results: From January 2000 to December 2021, 3109 patients with metastatic breast cancer were enrolled in the GIM14/BIO-META study. Among them, 2498 patients experienced first-line treatment failure. Overall, first-to-second line attrition was 9.0% (95% confidence interval 7.9% to 10.1%), with similar attrition for patients with hormone receptor-positive/HER2-negative (8.5%) and HER2-positive (7.1%) breast cancer. Patients with triple-negative disease experienced the highest attrition (13.0%). Age, menopausal status, disease-free interval from primary tumor diagnosis, type of metastatic spread, and tumor subtype independently predicted first-to-second-line attrition.

Conclusions: These findings could inform treatment decisions and guide clinical research on treatment sequencing. For instance, patients with the lowest risk of attrition may be the ideal candidates for trials exploring de-escalated first-line regimens, followed by more aggressive treatments upon progression.

Keywords: attrition; metastatic breast cancer; treatment line.

PubMed Disclaimer

Figures

Figure 1
Figure 1
STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) diagram.
Figure 2
Figure 2
Overallattrition rateandaccording to tumor subtype. Vertical bars represent 95% confidence intervals of the point estimate. HER2, human epidermal growth factor receptor 2; HR, hormone receptor.
See this image and copyright information in PMC

References

    1. Xu S., Liu Y., Zhang T., et al. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019. Front Oncol. 2021;11 - PMC - PubMed
    1. Caswell-Jin J.L., Plevritis S.K., Tian L., et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2(4) - PMC - PubMed
    1. Caswell-Jin J.L., Sun L., Munoz D., et al. Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017. J Clin Oncol. 2022;40(suppl 16):1008.
    1. Gennari A., Andre F., Barrios C.H., et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. - PubMed
    1. Seah D.S., Luis I.V., Macrae E., et al. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014;12(1):71–80. - PubMed

Publication types